RIPK2 induces docetaxel resistance in prostate cancer through the NF-κB/P-gp signaling pathway
Favorite
Share
More Options
14

Open in WPS to view all 14 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
